HAS Healthcare Advanced Synthesis (HAS), is a prominent player in the global chemical-pharmaceutical industry. With four decades of experience, HAS excels as a full-service contract development and manufacturing organization, offering high-quality, exclusive, tailored solutions, such as active pharmaceutical ingredients (APIs), high-potency active pharmaceutical ingredients (HPAPIs), and anticancer compounds, to pharmaceutical and biotechnology companies.
For forty years, HAS has been at the cutting edge of scientific and technological advancements, embracing innovation and sustainability. The company is committed to reducing its environmental footprint while enhancing its contributions to the local community.
This significant achievement is the result of a decade of innovative and sustainable initiatives taken by HAS, driven by a commitment to decarbonizing its activities across its value chain. One of the key projects contributing to the reduction of the company’s carbon footprint was the 2017 connection to the district heating system in Biasca, which reduced CO2e emissions from fossil fuels (heating oil) by over 90% through the use of biomass obtained sustainably from nearby forests.
Since 2021, HAS has achieved and maintained Carbon Neutral status. Every year, an external independent consultant calculates HAS’s CO2 emissions in line with the GHG Protocol and the ISO 14064-1 norm. The reporting scope takes into account HAS’s Scope 1, 2, and 3 emissions for the reference year. Details regarding the calculation and reporting of emissions are available in the 2023 HAS Healthcare Advanced Synthesis “Advancing Together” Sustainability Report.
In 2024, HAS celebrates its 40th anniversary by maintaining its carbon neutrality by offsetting the unavoidable CO2 emissions for 2023 through the purchase of Gold Standard certified credits. These credits are widely recognized for their effectiveness in offsetting greenhouse gas emissions: they are generated by projects that meet the stringent criteria established by the Gold Standard Foundation, a non-profit organization committed to ensuring environmental integrity and sustainable development. The Gold Standard certificates acquired by HAS support two impactful projects focused on providing clean water and low-emission cooking stoves to underserved communities in Ethiopia.
Dr. Waldo Mossi, PhD, CEO of HAS Healthcare Advanced Synthesis, stated: “At HAS, prioritizing investment in innovative technologies and facilities that reduce the environmental impact of our production activities is fundamental. Today, I am delighted to announce that our dedication to sustainable growth have enabled HAS Healthcare Advanced Synthesis to achieve carbon neutrality for 2023. This accomplishment clearly reflects our commitment to sustainable progress, environmental protection, and making positive contributions to our local communities.”
Our primary goal is to tackle future challenges by continuously enhancing our production capabilities to deliver the highest quality products to our customers. Simultaneously, we are deeply committed to environmental protection, promoting sustainability year after year. This commitment is evidenced by our ongoing investments in innovative technologies, such as our new cutting-edge Quality Control Laboratory Center designed to minimize our carbon footprint and preserve the environment, which was inaugurated earlier this year, on the occasion of our 40th anniversary.
About HAS Healthcare Advanced Synthesis
HAS Healthcare Advanced Synthesis, a CDMO with four decades of experience and excellence, offers a full range of customized services from laboratory development to manufacturing. HAS Healthcare Advanced Synthesis develops and produces active pharmaceutical ingredients (APIs), advanced intermediates, high-activity active pharmaceutical ingredients (HPAPIs) and anticancer compounds.
The production facility is located in Biasca, Switzerland, and was founded in 1984. The site is regularly inspected by SwissMedic, FDA and other global regulatory Agencies. The production scale ranges from a few hundred grams to tens of kilograms for highly active ingredients (HPAPI) and anticancer and from kilograms to tens of tons for standard active ingredients (APIs); the plants are completely dedicated to cGMP production.
For more information visit our website https://www.hashealthcare.com/ and follow us on Linkedin.
Contact Press Office
HAS Healthcare Advanced Synthesis
Biasca, Switzerland
Giacomo Braglia
Tel: +41 (0) 91 873 94 00
Email: [email protected]